Zhongyin Technology

Zhongyin Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of gene therapies for inherited retinal diseases (IRDs). The company leverages its proprietary AAV-based gene replacement and gene editing platforms to target conditions such as retinitis pigmentosa and Leber congenital amaurosis. Its lead candidate, ZVS101e, is an AAV-based gene therapy designed to treat RPGR-mutated X-linked retinitis pigmentosa and is currently undergoing clinical evaluation. Zhongyin Biotech aims to address significant unmet medical needs in ophthalmology through innovative genetic medicines. The company was founded by leading experts in ophthalmic genetics and is supported by prominent venture capital firms including Qiming Venture Partners.